Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 2
2011 4
2012 3
2013 3
2014 5
2015 1
2016 2
2017 1
2018 3
2019 3
2020 1
2021 6
2022 7
2023 12
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Hanania NA, et al. Among authors: altincatal a. Ann Allergy Asthma Immunol. 2023 Feb;130(2):206-214.e2. doi: 10.1016/j.anai.2022.10.018. Epub 2022 Nov 2. Ann Allergy Asthma Immunol. 2023. PMID: 36332763 Free article. Clinical Trial.
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Pavord ID, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Jul;12(7):1763-1772. doi: 10.1016/j.jaip.2024.03.031. Epub 2024 Mar 29. J Allergy Clin Immunol Pract. 2024. PMID: 38555079 Free article. Clinical Trial.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Fox RJ, et al. Among authors: altincatal a. Neurology. 2024 May 14;102(9):e209357. doi: 10.1212/WNL.0000000000209357. Epub 2024 Apr 22. Neurology. 2024. PMID: 38648580 Free PMC article. Clinical Trial.
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, Altincatal A, Mannent LP, Amin N, Laws E, Akinlade B, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Bacharier LB, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Apr;12(4):948-959. doi: 10.1016/j.jaip.2023.12.006. Epub 2023 Dec 11. J Allergy Clin Immunol Pract. 2024. PMID: 38092225 Free article. Clinical Trial.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: altincatal a. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.
Pavord ID, Rabe KF, Israel E, Szefler SJ, Brusselle G, Pandit-Abid N, Altincatal A, Chen Z, Amin N, Khan AH, Lederer DJ, Zhang Y, Rowe PJ, Deniz Y, Radwan A, Jacob-Nara JA, Busse WW. Pavord ID, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2025 Jan;13(1):132-142. doi: 10.1016/j.jaip.2024.10.009. Epub 2024 Oct 16. J Allergy Clin Immunol Pract. 2025. PMID: 39424189 Free article.
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE).
Maspero JF, Antila MA, Deschildre A, Bacharier LB, Altincatal A, Laws E, Mortensen E, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Maspero JF, et al. Among authors: altincatal a. J Allergy Clin Immunol Pract. 2024 Dec;12(12):3303-3312. doi: 10.1016/j.jaip.2024.08.038. Epub 2024 Aug 28. J Allergy Clin Immunol Pract. 2024. PMID: 39209068 Free article. Clinical Trial.
52 results